UK In Vivo Cro Market Size & Outlook, 2024-2030
Related Markets
UK in vivo cro market highlights
- The UK in vivo cro market generated a revenue of USD 291.5 million in 2023 and is expected to reach USD 495.4 million by 2030.
- The UK market is expected to grow at a CAGR of 7.9% from 2024 to 2030.
- In terms of segment, small molecule was the largest revenue generating modality type in 2023.
- Large Molecule is the most lucrative modality type segment registering the fastest growth during the forecast period.
In vivo cro market data book summary
| Market revenue in 2023 | USD 291.5 million |
| Market revenue in 2030 | USD 495.4 million |
| Growth rate | 7.9% (CAGR from 2023 to 2030) |
| Largest segment | Small molecule |
| Fastest growing segment | Large Molecule |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Small Molecule, Large Molecule |
| Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Other key industry trends
- In terms of revenue, UK accounted for 6.3% of the global in vivo cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany in vivo cro market is projected to lead the regional market in terms of revenue in 2030.
- Spain is the fastest growing regional market in Europe and is projected to reach USD 328.5 million by 2030.
Small molecule was the largest segment with a revenue share of 63.64% in 2024. Horizon Databook has segmented the UK in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
The UK is expected to play a significant role in the Europe in vivo CRO market. The growth is primarily due to the development of the preclinical services market in the country. Outsourced preclinical services are expected to witness rapid growth due to increasing demand for improved test outcomes at lower costs by pharmaceutical companies.
Pharmaceutical and biotech companies in the UK rely on in vivo services offered by CROs to develop new medicines and meet the demand for advanced new treatments. To reduce animal usage in research and enhance animal welfare, the UK government established the National Centre for the Replacement, Refinement, & Reduction of Animals in Research (NC3Rs) in 2004.
The principles of the 3Rs (Replacement, Refinement, & Reduction) provide an ethical and legal structure for in vivo research. The NC3Rs collaborates with CROs, pharmaceutical & biotech companies, regulators, and experts in monoclonal antibodies to identify new in vivo techniques & minimize the reliance on animals. This is expected to increase the adoption of advanced in vivo techniques, leading to market growth.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
In Vivo CRO Market Scope
In Vivo CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK in vivo cro market size, by modality type, 2018-2030 (US$M)
UK In Vivo CRO Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
